Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy.

BACKGROUND Patients with diabetes are at increased risk of death after acute myocardial infarction, independent of other baseline risk factors and more severe coronary artery disease. We studied the angiographic and electrocardiographic responses to thrombolytic agents in patients with diabetes; in particular ST-segment resolution as a measure of microvascular flow. METHODS Angiography was performed in 2588 patients at 90 minutes after thrombolytic agent administration as well as after percutaneous coronary intervention (PCI) in the Thrombolysis In Myocardial Infarction (TIMI) 4, 10A, 10B, and 14 trials. Electrocardiographic parameters were assessed at baseline and at 90 minutes in the TIMI 14 trial. RESULTS Compared with those without diabetes, patients with diabetes (347/2588 [13.4%]) were older, more often female, heavier, and less often smokers, and they had higher systolic blood pressure on admission. At angiography, they more frequently had 3-vessel disease, well-developed collateral vessels, more distal culprit lesions, and smaller reference segment diameters. In the infarct-related artery, there was no relationship between diabetes and TIMI 3 flow at 90 minutes (55.4% vs 59.0% without diabetes) or after PCI, (83.7% vs 84.2%, both P = NS). Corrected TIMI frame counts were also similar at both time points. However, there was less frequent complete ST-segment resolution among diabetic patients after thrombolysis (38.6% vs 49.2%, adjusted P =.04). CONCLUSION Thrombolysis and adjunctive/rescue PCI achieved equal rates of epicardial flow in patients with and without diabetes. However, diabetic patients had less complete ST-segment resolution, suggesting impaired microvascular flow. Abnormal microvascular flow may contribute at least in part to the poorer outcomes observed in patients with diabetes and acute myocardial infarction.

[1]  E. Antman,et al.  Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. , 2001, American heart journal.

[2]  E. Antman,et al.  Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. , 2000, European heart journal.

[3]  B. Gersh,et al.  Time to Presentation With Acute Myocardial Infarction in the Elderly: Associations With Race, Sex, and Socioeconomic Characteristics , 2000, Circulation.

[4]  W. Dassen,et al.  Angiographic assessment of prospectively determined non-invasive reperfusion indices in acute myocardial infarction , 2000, Heart.

[5]  J P Ornato,et al.  Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. , 2000, JAMA.

[6]  R. Califf,et al.  Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: Lessons from the GUSTO-IIb Angioplasty Substudy , 2000 .

[7]  R. Klein,et al.  The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. , 2000, Archives of internal medicine.

[8]  E. Antman,et al.  ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. , 2000, The American journal of cardiology.

[9]  C M Gibson,et al.  Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.

[10]  G. Watts,et al.  Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria. , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[11]  E. Braunwald,et al.  Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. , 1999, Circulation.

[12]  C. Vrints,et al.  Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. , 1999, Circulation.

[13]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[14]  D. Freimark,et al.  The distinction between coronary and myocardial reperfusion after thrombolytic therapy by clinical markers of reperfusion. , 1998, Journal of the American College of Cardiology.

[15]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[16]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[17]  T. Kawamoto,et al.  Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus. , 1997, Journal of the American College of Cardiology.

[18]  R. Califf,et al.  Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction , 1997 .

[19]  J. Chesebro,et al.  Mechanisms Determining Course and Outcome of Diabetic Patients Who Have Had Acute Myocardial Infarction , 1997, Annals of Internal Medicine.

[20]  E. Braunwald,et al.  TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.

[21]  R. Califf,et al.  Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. , 1996, Journal of the American College of Cardiology.

[22]  D. Faxon,et al.  Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1996, Circulation.

[23]  K Wegscheider,et al.  Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. , 1995, Journal of the American College of Cardiology.

[24]  M. Winniford,et al.  Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. , 1995, Circulation.

[25]  C. Cannon,et al.  Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.

[26]  K. Wegscheider,et al.  Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. , 1994, Journal of the American College of Cardiology.

[27]  A. Nitenberg,et al.  Impairment of Coronary Vascular Reserve and ACh-Induced Coronary Vasodilation in Diabetic Patients With Angiographically Normal Coronary Arteries and Normal Left Ventricular Systolic Function , 1993, Diabetes.

[28]  R. Califf,et al.  Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. , 1993, Journal of the American College of Cardiology.

[29]  L. Wilkins Early Effects of Tissue‐Type Plasminogen Activator Added to Conventional Therapy on the Culprit Coronary Lesion in Patients Presenting With Ischemic Cardiac Pain at Rest Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trialx , 1993, Circulation.

[30]  R. Nesto,et al.  Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. , 1992, Journal of the American College of Cardiology.

[31]  T Sandor,et al.  Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. , 1992, The American journal of cardiology.

[32]  D L McGee,et al.  Diabetes and Cardiovascular Risk Factors: The Framingham Study , 1979, Circulation.

[33]  A. Terzic,et al.  Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. , 1999, Journal of the American College of Cardiology.

[34]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[35]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.